

Long-term tolerance of different doses of NUTRIOSE®FB 06 in male adults

W.J. PASMÁN¹, D. WILS², A.F.M. KARDINAAL¹, L. LAFAY³ and M.H. SANIEZ²

1- TNO Nutrition and Food Research, Department of Nutritional Physiology, PO Box 360, 3700 AJ, Zeist, The Netherlands

2- ROQUETTE Frères, Toxicology and Nutrition Department, 62080 LESTREM Cedex, France

3- PROTEINES Healthcare, 6 rue Guillaume Tell, 75017 PARIS, France

INTRODUCTION

NUTRIOSE®FB 06 is a wheat starch based, weakly digested food dextrin, containing about 85% of soluble dietary fibres. In a previous study, it was demonstrated that NUTRIOSE®FB 06, when consumed for seven days, was well-tolerated up to a daily dose of 45g and that this product had fibre effects. The aim of the present study was to determine the gastro-intestinal tolerance of 30 and 45g of NUTRIOSE®FB 06 consumed by humans for 4-5 weeks, to study the long-term modification of colon microflora and to compare the results with consumption of the completely digested standard GLUCIDEX®6 maltodextrin.

MATERIALS AND METHODS

Subjects

- ➔ 48 healthy men
- ➔ Age 20-45 years
- ➔ BMI ≤31 kg/m²

Design

- ➔ Randomized study
- ➔ Placebo controlled
- ➔ Double blind
- ➔ 3 parallel treatments
- ➔ After a run-in period of one week, subjects consumed half the dose of study substance during the first week and then the full dose of study substance for four weeks

- ➔ The placebo group consumed 22.5g GLUCIDEX®6. The treated groups consumed 30 or 45g NUTRIOSE®FB 06 per day (the placebo group and the group treated with the greater amount of NUTRIOSE®FB 06 ingested the same energy content).
- ➔ Each dose was consumed in four equal portions at breakfast, morning, lunch and dinner for 28 days.
- ➔ Subjects restricted their fibre intake and excluded pre- and probiotics from their diet.

Study parameters

- ➔ Adverse events by daily well-being questionnaires and a diary.
- ➔ Faecal analyses: pH, microbiology, enzymatic activities, residue of NUTRIOSE®FB 06 estimated by polymerized glucose.
- ➔ Anthropometry: body weight, body composition by the bio-impedance method.

RESULTS AND DISCUSSION

Compliance

- ➔ The drop-out rate of the study was 10%, not, or unlikely to have been, related to the study treatment.

Digestive tolerance

- ➔ No serious adverse events occurred. The complaint “rumbling of the stomach” disappeared over time.
- ➔ No diarrhoea was reported.
- ➔ Both NUTRIOSE®FB 06 dosages were well tolerated.

Faecal analyses (Fig. 1)

- ➔ Faecal pH decreased after three weeks time and treatment from 6.5-6.6 (all treatments at the start of the study) to 6.1 for both NUTRIOSE®FB 06 treatments at day 35 (the end of the study).
- ➔ Total glucosidases (α and β) increased significantly with NUTRIOSE®FB 06 treatments.
- ➔ Data showed an increase in Lactobacilli for day 35 versus day -1 for 45g (7.2 vs 8.2 log cfu/g faeces) on NUTRIOSE®FB 06 treatment and a trend towards a lower number of Clostridia (5.9 vs 5.6 log cfu/g faeces).

Anthropometry (Table I)

- ➔ Body weight in both NUTRIOSE®FB 06 groups remained stable, whereas the reference group showed a small increase. Although no significant difference was found (p=0.07), the trend is a promising result because of the shortness of the treatment period.

Fig. 1: Faecal parameters following 35 days consumption of NUTRIOSE®FB 06 or placebo




Table I: Mean body weight (kg) at the first and last day of the study

Treatment	Placebo	NUTRIOSE®FB 06 30g	NUTRIOSE®FB 06 45g
Day -1	80.4 ± 11.8	82.1 ± 12.0	86.0 ± 12.9
Day 35	81.2 ± 11.9	82.1 ± 11.6	86.0 ± 12.6
Difference	0.8	0.0	0.0

CONCLUSION

The dietary fibre NUTRIOSE®FB 06 is a fermentable carbohydrate, well tolerated in the long-term at 30-45g daily. No negative effects were found on gastrointestinal parameters.

The product was well fermented, which resulted in an increase in Lactobacilli and α - β glucosidases and a decrease in the faecal pH. A trend in decrease of Clostridia was also observed.

We also observed a trend towards better weight maintenance with the dietary fibre NUTRIOSE®FB 06, which is promising.

Long-term tolerance of different doses of NUTTRIOSE®FB 06 in male adults

The information contained in this document is to the best of our knowledge true and accurate but all instructions, recommendations or suggestions are made without guarantee.

Since the conditions of use are beyond our control, we disclaim any liability for loss and/or damage suffered from use of these data or suggestions.

Furthermore, no liability is accepted if use of any product in accordance with these data or suggestions infringes any patent. No part of this document may be reproduced by any process without our prior written permission.

© Roquette Frères S.A. - 09/04

W.J. PASMANN¹, D. WILS², A.F.M. KARDINAAL¹, L. LAFAY³ and M.H. SANIEZ¹

1- TNO Nutrition and Food Research, Department of Nutritional Physiology, PO Box 360, 3700 AL Zeist, The Netherlands

2- ROQUETTE Frères, Toxicology and Nutrition Department, 62080 LESTREM Cedex, France

3- PROTEINES Healthcare, 6 rue Guillaume Tell, 75017 PARIS, France